Anavex Life Sciences Corp. - Exhibit 10.1 - Filed by newsfilecorp.com






CONSULTING AGREEMENT 

                    THIS
CONSULTING AGREEMENT (the “Agreement”) is made as of the 2nd day of August,
2010 (the “Effective Date”), and is by and between Anavex Life Sciences Corp. A
Nevada State Corporation (“Company”), and Mr. Tom Skarpelos, with an
address at 1288 Alberni Street, Vancouver, B.C. (“Consultant”). 

W I T N E S S E T H: 

                    WHEREAS
the Consultant is the founder and major shareholder of the Company and has
considerable insight into the ongoing operations of the Company. 

                    WHEREAS
the Company wishes to engage the services of the Consultant to assist the
Company in the advancement of drug candidates and corporate development. 

                    AND
WHEREAS Consultant wishes to perform such services among others for and on
behalf of the Company and the Company desires to obtain and apply the expertise
of the Consultant to the business of the company.

                    NOW
THEREFORE THIS AGREEMENT WITNESSES that for good and valuable consideration
(the receipt of which is hereby acknowledged by each of the parties hereto) the
parties make the arrangements and acknowledgements hereinafter set forth: 

1.           Consulting
Services - The Company hereby retains the services of the Consultant and
the Consultant hereby agrees to provide the consulting services (the “Services”)
to the Company described in this Agreement, by providing such Services to
benefit the Company and its determination and implementation of the Company's
plans for its Business. 

2.           Term
- This Agreement is effective as of the Effective Date and shall remain in
force, for a period of 1 (one) year.

3.           Compensation
- In full consideration of the Consultant's Services hereunder, the Company
shall compensate the Consultant a fee as follows: 

               a.
Pay to the Consultant a fee of US$15,000.00 per month. 

4.           Non-Disclosure
of Information Consultant acknowledges that by virtue of his position he
will be privy to Company’s confidential information and trade secrets, as they
may exist from time to time, and that such confidential information and trade
secrets may constitute valuable, special, and unique assets of Company
(hereinafter collectively “Confidential Information”). Accordingly, Consultant
shall not, during the Term and for a period of one (1) year thereafter,
intentionally disclose all or any part of the Confidential Information to any
person, firm, corporation, association or any other entity for any reason or
purpose whatsoever, nor shall Consultant and any other person by, through or
with Consultant, during the term and for a period of one (1) year thereafter,
intentionally make use of any of the Confidential Information for any purpose or
for the benefit of any other person or entity, other than Company, under any
circumstances. 

5.          
Insider Trading – Consulting has received the Insider Trading
Policy of the Company and agrees to execute and abide by said Policy. 

                    IN
WITNESS WHEREOF, each of the parties hereto has executed as of the date
first herein above written. 

	COMPANY: 	CONSULTANT: 
	  	  
	Anavex Life Sciences Corp. 	/s/ Tom Skarpelos 
	  	Mr. Tom Skarpelos 
	By:/s/ Harvey Lalach 	  
	       Harvey Lalach 	  
	       President 	  
	  	  
	By: /s/ Cameron Durrant 	  
	       Cameron Durrant
    	  
	       Executive
      Chairman